- Trials with a EudraCT protocol (6,602)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6,602 result(s) found for: Phase Change.
Displaying page 1 of 331.
EudraCT Number: 2013-003542-17 | Sponsor Protocol Number: CU-LATER | Start Date*: 2014-06-11 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with r... | ||
Medical condition: Chronic Spontaneous Urticaria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2018-003062-13 | Sponsor Protocol Number: AZP01-CLI-003 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Millendo Therapeutics SAS | |||||||||||||
Full Title: A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome | |||||||||||||
Medical condition: Prader-Willi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003578-34 | Sponsor Protocol Number: 54135419TRD3008 | Start Date*: 2016-08-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | |||||||||||||
Medical condition: Treatment-resistant Major Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) PL (Completed) HU (Completed) CZ (Completed) SK (Completed) LT (Completed) AT (Completed) FI (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004587-38 | Sponsor Protocol Number: ESKETINTRD3004 | Start Date*: 2015-08-05 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression | |||||||||||||
Medical condition: Treatment-resistant Major Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) ES (Completed) GB (Completed) AT (Completed) PL (Completed) BG (Completed) LT (Completed) FI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001910-13 | Sponsor Protocol Number: AV-101-002 | Start Date*: 2022-02-21 | ||||||||||||||||||||||||||
Sponsor Name:Aerovate Therapeutics, Inc. | ||||||||||||||||||||||||||||
Full Title: IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hy... | ||||||||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Ongoing) NL (Ongoing) CZ (Trial now transitioned) PT (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000148-24 | Sponsor Protocol Number: 1 | Start Date*: 2018-06-14 |
Sponsor Name:Norwegian University of Science and Technology | ||
Full Title: Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: the ExPlas Study | ||
Medical condition: Early Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001395-37 | Sponsor Protocol Number: Repha_1430 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Repha GmbH | |||||||||||||
Full Title: Investigation of the efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in adult patients with acute bronchitis. A multicenter, randomized, double-blind, placebo-controlled, parallel-grou... | |||||||||||||
Medical condition: acute bronchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000699-39 | Sponsor Protocol Number: FGCL-3019-094 | Start Date*: 2021-11-04 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Ambulatory Subjects with Duchenne Muscular Dystrophy (DMD) | |||||||||||||
Medical condition: Ambulatory Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) AT (Prematurely Ended) NL (Completed) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001674-34 | Sponsor Protocol Number: AG348-C-020 | Start Date*: 2022-02-17 | |||||||||||
Sponsor Name:AGIOS PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) FR (Ongoing) BE (Ongoing) DE (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002442-23 | Sponsor Protocol Number: GS-US-428-4025 | Start Date*: 2017-01-09 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis | |||||||||||||
Medical condition: Primary Sclerosing Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004451-40 | Sponsor Protocol Number: H15/02 | Start Date*: 2016-02-17 | |||||||||||
Sponsor Name:Almirall Hermal GmbH | |||||||||||||
Full Title: SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL | |||||||||||||
Medical condition: Moderate to severe spasticity due to MS (multiple sclerosis). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000645-14 | Sponsor Protocol Number: EFC16035 | Start Date*: 2020-10-13 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) | |||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) BG (Ongoing) EE (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing) NO (Temporarily Halted) CZ (Ongoing) GR (Ongoing) LV (Ongoing) DE (Restarted) BE (Ongoing) HU (Ongoing) NL (Restarted) PT (Ongoing) IT (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001277-23 | Sponsor Protocol Number: ARGX-113-2007 | Start Date*: 2022-10-26 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Phar... | |||||||||||||
Medical condition: Active Idiopathic Inflammatory Myopathy (IIM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) LT (Ongoing) SE (Ongoing) DE (Ongoing) HU (Ongoing) IE (Ongoing) AT (Ongoing) ES (Ongoing) PT (Ongoing) IT (Ongoing) SK (Ongoing) PL (Ongoing) BG (Ongoing) GR (Ongoing) CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003690-21 | Sponsor Protocol Number: R10933-10987-COV-2067 | Start Date*: 2020-10-06 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19 | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004395-22 | Sponsor Protocol Number: 402-C-1603 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:Reata Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome | |||||||||||||
Medical condition: Alport Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002299-41 | Sponsor Protocol Number: KY1005-CT02 | Start Date*: 2019-01-24 | |||||||||||
Sponsor Name:Kymab Limited | |||||||||||||
Full Title: A Phase IIa, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001108-40 | Sponsor Protocol Number: MK-5475-007 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) GR (Trial now transitioned) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000485-36 | Sponsor Protocol Number: G0500705 | Start Date*: 2006-08-23 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust | ||
Full Title: A randomised, double blind, placebo controlled study to Assess The Effect of Antibiotic Therapy on Chronic Rejection in Human Lung Transplantation | ||
Medical condition: Post Lung Transplantation Chronic Rejection identified as bronchiolitis obliterans syndrome (BOS) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002640-25 | Sponsor Protocol Number: 217-MDD-302 | Start Date*: 2019-12-09 | |||||||||||
Sponsor Name:Sage Therapeutics, Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DIS... | |||||||||||||
Medical condition: MAJOR DEPRESSIVE DISORDER | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003764-27 | Sponsor Protocol Number: HS-20-677 | Start Date*: 2022-09-20 |
Sponsor Name:Camurus AB | ||
Full Title: A randomized, placebo-controlled, double-blind, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease | ||
Medical condition: Polycystic liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Ongoing) BE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.